Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.48 |
| ▸ | NMBR | P28336 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384822 | 0.88 | PTPN1 (0.44) | PTPN1NMBRMDM4TP53SIRT2 | |
| SCHEMBL29759585 | 0.87 | NMBR (0.47) | PTPN1NMBRMDM4TP53SIRT2 | |
| SCHEMBL29427171 | 0.85 | NMBR (0.48) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL30185441 | 0.83 | PTPN1 (0.41) | PTPN1MDM4TP53GRB2 | |
| SCHEMBL30385679 | 0.83 | MDM4 (0.49) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL30385359 | 0.83 | PTPN1 (0.38) | PTPN1NMBRMDM4TP53SIRT2 | |
| SCHEMBL29839944 | 0.82 | NMBR (0.46) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL30250367 | 0.82 | NMBR (0.42) | NMBRSIRT2 | |
| SCHEMBL30641716 | 0.81 | PTPN1 (0.40) | PTPN1NMBRMDM4TP53SIRT2 | |
| SCHEMBL30385094 | 0.79 | PTPN1 (0.59) | PTPN1HDAC1HDAC2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | Shenzhen JYMed Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | GCG, GLP1R, DPP7 | PTPN1 2050/4885NMBR 3029/4885MDM4 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.